NewsRx

Search our medical news database

HST Global, Inc.

HST Global Enters into Letter of Intent to Acquire Treatment Facility

Published in Cancer Weekly, May 5th, 2009

HST Global, Inc. (OTCBB:HSTC) announced it is reaching across the globe to insure that immunotherapy and alternative treatments and solutions are available to all communities. Alternative therapies are achieving extraordinary degrees of success, as demonstrated by companies such as Dendreon Corporation (NASDAQ:DNDN) whose immunotherapy prostate-cancer drug Provenge was found to extend survival rates. HST anticipates completing the acquisition of the center in the next ninety (90) days.

Ron Howell, President and CEO of HST Global, Inc. stated, “HST is excited to have completed the initial documentation necessary to initiate the acquisition of our first Health and...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook